<SEC-DOCUMENT>0001075880-13-000028.txt : 20130408
<SEC-HEADER>0001075880-13-000028.hdr.sgml : 20130408
<ACCEPTANCE-DATETIME>20130408090700
ACCESSION NUMBER:		0001075880-13-000028
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130408
FILED AS OF DATE:		20130408
DATE AS OF CHANGE:		20130408

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		13747444

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>aform6kproforma.htm
<DESCRIPTION>CONVERTED BY EDGARWIZ
<TEXT>
<HTML>
<head><title>Converted by EDGARwiz</title> </head> <body style="MARGIN-TOP:0px; FONT-FAMILY:Times New Roman; COLOR:#000000; FONT-SIZE:10pt"> <div style=WIDTH:601px> <p style="LINE-HEIGHT:12pt; MARGIN:0px; PADDING-LEFT:56px" align=center><b>UNITED STATES </b></p> <p style="LINE-HEIGHT:12pt; MARGIN:0px; PADDING-LEFT:56px" align=center><b>SECURITIES AND EXCHANGE COMMISSION </b></p> <p style="LINE-HEIGHT:12pt; MARGIN:0px; PADDING-LEFT:56px" align=center><b>Washington, D.C. 20549 </b></p> <p style="TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=justify>&nbsp;</p> <p style="MARGIN-TOP:0px; PADDING-LEFT:56px; MARGIN-BOTTOM:16px; FONT-SIZE:14pt" align=center><b>Form 6-K </b></p> <p style="LINE-HEIGHT:14.4pt; MARGIN-TOP:0px; PADDING-LEFT:56px; MARGIN-BOTTOM:14px; FONT-SIZE:11.5pt" align=center><b>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 </b></p> <p style="LINE-HEIGHT:12pt; TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=left>For the month of April, 2013. </p> <p style="LINE-HEIGHT:12pt; TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=justify>Commission File Number ________________ </p> <p style="LINE-HEIGHT:12pt; MARGIN:0px" align=center><br></p> <p style="LINE-HEIGHT:12pt; MARGIN:0px; PADDING-LEFT:56px; FONT-SIZE:20pt" align=center><b>Novogen Limited</b></p> <p style="LINE-HEIGHT:12pt; MARGIN:0px; PADDING-LEFT:56px" align=center>(Translation of registrant<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s name into English) </p> <p style=MARGIN:0px align=justify><br></p> <p style="MARGIN:0px; PADDING-LEFT:56px; FONT-SIZE:12pt" align=center>1-7 Waterloo Road, Macquarie Park, NSW, Australia</p> <p style="LINE-HEIGHT:12pt; MARGIN-TOP:0px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px" align=center>(Address of principal executive office) </p> <p style="LINE-HEIGHT:13.55pt; TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px; PADDING-RIGHT:71px" align=left>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</p> <table style="MARGIN-TOP:0px; FONT-SIZE:10pt" cellpadding=0 cellspacing=0> <tr style=FONT-SIZE:0px> <td width=585 /> </tr><tr> <td width=585 style=MARGIN-TOP:0px valign=top> <p style="TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=justify>&nbsp;Form 20-F<font style=FONT-FAMILY:Wingdings> </font><font style=FONT-FAMILY:Wingdings><font face=Wingdings>x</font>&nbsp;</font><font style="FONT-FAMILY:Wingdings 2">&nbsp;</font>Form 40-F<font style=FONT-FAMILY:Wingdings> </font><font face=Wingdings>o</font></p></td></tr></table> <p style="LINE-HEIGHT:13.55pt; TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px; PADDING-RIGHT:71px" align=justify><b>&nbsp;</b>&nbsp;</p> <p style="LINE-HEIGHT:12pt; MARGIN-TOP:0px; TEXT-INDENT:-56px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px" align=justify>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <font face=Wingdings>o</font></p> <p style="LINE-HEIGHT:12pt; MARGIN-TOP:0px; TEXT-INDENT:-56px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px" align=justify><b>Note</b>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </p> <p style="LINE-HEIGHT:12pt; MARGIN-TOP:0px; TEXT-INDENT:-56px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px" align=justify>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<font face=Wingdings>o</font></p> <p style="LINE-HEIGHT:12pt; MARGIN-TOP:0px; TEXT-INDENT:-56px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px" align=justify><b>Note</b>: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>home country<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font>), or under the rules of the home country exchange on which the registrant<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </p> <p style="LINE-HEIGHT:12pt; MARGIN-TOP:0px; TEXT-INDENT:-56px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px" align=justify>Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. &nbsp;Yes&nbsp;&nbsp;<font style="FONT-FAMILY:Wingdings 2"><font face=Wingdings>o</font>&nbsp;</font>No <font face=Wingdings>x</font></p> <p style="TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=justify>If <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>yes<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font> is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)</p> <p style="LINE-HEIGHT:12pt; MARGIN:0px" align=center><br></p> <p style="LINE-HEIGHT:12pt; MARGIN:0px; PADDING-LEFT:56px" align=center><b>SIGNATURES </b></p> <p style="LINE-HEIGHT:12pt; MARGIN-TOP:0px; TEXT-INDENT:-56px; PADDING-LEFT:56px; MARGIN-BOTTOM:13px" align=justify><b>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf</b> by the undersigned, thereunto duly authorized. </p> <p style="LINE-HEIGHT:12pt; MARGIN-TOP:0px; TEXT-INDENT:-56px; PADDING-LEFT:56px; PADDING-RIGHT:20px; MARGIN-BOTTOM:13px" align=justify><b>Novogen Limited</b> (Registrant) </p> <p style="TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=justify>&nbsp;</p> <p style="TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=justify>(Signature) *</p> <p style="TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=justify>Andrew Bursill</p> <p style="TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=justify>&nbsp;</p> <p style="TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px" align=justify>Date 8 April 2013</p> <p style=MARGIN:0px align=justify><br></p> <p style="TEXT-INDENT:-56px; MARGIN:0px; PADDING-LEFT:56px; FONT-FAMILY:ClassGarmnd BT,Times New Roman; FONT-SIZE:9pt" align=justify>* Print the name and title under the signature of the signing officer.</p> <p style=MARGIN:0px align=justify><br><br></p></div></body>
<!-- EDGAR Validation Code: 9AF0549E -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>cs6chiralbraincancerdataanno.htm
<DESCRIPTION>CONVERTED BY EDGARWIZ
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>Converted by EDGARwiz</TITLE>
</HEAD>
<BODY style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:625.267px"><P style="margin-top:66.2px; margin-bottom:0px"><img src="cs6chiralbraincancerdataa001.jpg" alt="[cs6chiralbraincancerdataa001.jpg]" align=bottom height=70.4 width=550.4></P>
<P style="margin-top:20.467px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><B>ASX Release</B></P>
<P style="margin-top:21.6px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><B>8 April 2013</B></P>
<P style="margin-top:21.467px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><B>Novogen Announces Successful Isolation of Most Potent Form of CS-6</B></P>
<P style="margin-top:21.6px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">CS-6 is the lead anti-cancer drug candidate being developed by Novogen as a</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">first-in-class comprehensive cancer therapy.</P>
<P style="margin-top:21.467px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">In manufacturing terms, CS-6 is classified as a chiral molecule, meaning that the</P>
<P style="margin-top:2.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">molecule can exist in both left- and right-hand forms known as enantiomers. This</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">tendency is common to most drugs as well as to many naturally-occurring</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">molecules.</P>
<P style="margin-top:21.467px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">This significance of this to the pharmaceutical industry is that enantiomers often</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">differ in their biological activity, with one form being more active than the other</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">form. This difference can lead to the weakest form inhibiting the most active</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">form. Where that happens, the enantiomers need to be separated and used in</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">isolation.</P>
<P style="margin-top:21.6px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">The initial biological studies on CS-6 have been conducted using a mixture of the</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">two enantiomers. This is a typical research strategy in early-stage drug</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">development to save time and costs. Purification and manufacture of the pure</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">left- and right hand forms is only undertaken once a molecule has demonstrated</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">significant promise in pre-clinical studies. With CS-6 now having shown that</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">promise, the Company recently undertook manufacture of pure left- and right-</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">hand forms, representing a significant advance in its developmental pathway.</P>
<P style="margin-top:21.6px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">The two CS-6 enantiomers were screened recently<I> in vitro</I> for activity against</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">brain cancer (glioblastoma and meduloblastoma) cell lines. Analysis of this data</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">today shows that one CS-6 enantiomer is approximately 200 times more active</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">than the alternate form of CS-6 against all brain cancer cell lines tested.</P>
<P style="margin-top:21.6px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Novogen Chief Scientific Officer, Dr Andrew Heaton, today said, <font style='font-family:Arial Unicode MS,Times New Roman'>&#8220;</font>The ability to</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">manufacture CS-6 in both left- and right-hand forms represents a significant</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">milestone in the development of this compound. The indication that one form of</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">CS-6 is active at nanomolar concentrations against a broad spectrum of brain</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">cancer lines is exciting and indicates that the earlier potencies we have seen</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">against cancer cells and cancer stem cells are likely to be even greater with the</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">purified enantiomer. We are now positioned to rapidly progress CS-6 to the</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">clinic.<font style='font-family:Arial Unicode MS,Times New Roman'>&#8221;</font></P>
<P style="margin-top:21.467px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><B>About Novogen</B></P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Novogen Ltd is a public Australian biotechnology company whose shares trade</P>
<P style="margin-top:5.133px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">on both the Australian Stock Exchange (symbol <font style='font-family:Arial Unicode MS,Times New Roman'>&#8216;</font>NRT<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>) and NASDAQ (symbol</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><font style='font-family:Arial Unicode MS,Times New Roman'>&#8216;</font>NVGN<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>). &nbsp;The Company is based in Sydney, Australia and is focused on the</P>
<P style="margin-top:4.933px; margin-bottom:0px"><BR>
<BR></P>
<P style="margin-top:72.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt; page-break-before:always">development of a family of novel anti-cancer drugs based on comprehensive</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">anti-cancer activity against both cancer cells and cancer stem cells. The</P>
<P style="margin-top:5px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Company<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s inaugural drug candidate is CS-6.</P>
<P style="margin-top:27.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><B>About CS-6</B></P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">CS-6 belongs to a new class of drug candidates intended to treat most forms of</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">cancer in a comprehensive manner, targeting both cancer cells and their</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">progenitor cells <font style='font-family:Arial Unicode MS,Times New Roman'>&#8230;</font>. cancer stem cells. CS-6 shows broad anti-proliferative and</P>
<P style="margin-top:5.133px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">cytotoxic activity against human cancer cells and ovarian cancer stem cells. CS-6</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">also has been designed deliberately to meet the major known criteria for</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">crossing the blood-brain barrier, and for that reason is being developed as a</P>
<P style="margin-top:4.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">first-line for the treatment of glioblastoma multiforme, the main form of primary</P>
<P style="margin-top:5.133px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">brain cancer.</P>
<P style="margin-top:27.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><B>About Cancer Stem Cells</B></P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Cancer stem cells (CSC) (or tumour-initiating cells) are believed to be a</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">subpopulation of cells within many types of cancer that are responsible for</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">driving the growth and spread of the cancer. CSC typically are resistant to</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">radiotherapy and chemotherapy and are thought to be responsible for cancer</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">recurrence following therapy. Targeting CSC is a new direction in oncology drug</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">development as a means of preventing cancer recurrence.</P>
<P style="margin-top:59.067px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><B>Further information</B></P>
<P style="margin-top:5px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Contact Dr Graham Kelly, Chief Executive Officer.</P>
<P style="margin-top:27.667px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">T: &nbsp;(61 2) 9878 0088</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">M: (61) 0459 200 095</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">E: Graham.Kelly@novogen.com</P>
<P style="margin-top:23.667px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Further information is available on the Company<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s web site, www.novogen.com</P>
<P style="margin-top:23.667px; margin-bottom:0px"><BR>
<BR></P>
</DIV></BODY>
<!-- EDGAR Validation Code: B5E3D414 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cs6chiralbraincancerdataa001.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cs6chiralbraincancerdataa001.jpg
M_]C_X``02D9)1@`!`0$```````#_X0"N17AI9@``34T`*@````@``8=I``0`
M```!````&@```````9*&``<```!Z````+`````!53DE#3T1%``!#`%(`10!!
M`%0`3P!2`#H`(`!G`&0`+0!J`'``90!G`"``=@`Q`"X`,``@`"@`=0!S`&D`
M;@!G`"``20!*`$<`(`!*`%``10!'`"``=@`V`#(`*0`L`"``<0!U`&$`;`!I
M`'0`>0`@`#T`(``Y`#``"O_^`#Q#4D5!5$]2.B!G9"UJ<&5G('8Q+C`@*'5S
M:6YG($E*1R!*4$5'('8V,BDL('%U86QI='D@/2`Y,`H`_]L`0P`(!@8'!@4(
M!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N)R`B+",<'"@W*2PP,30T
M-!\G.3TX,CPN,S0R_]L`0P$)"0D,"PP8#0T8,B$<(3(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R_\``$0@`@`/H
M`P$B``(1`0,1`?_$`!\```$%`0$!`0$!```````````!`@,$!08'"`D*"__$
M`+40``(!`P,"!`,%!00$```!?0$"`P`$$042(3%!!A-180<B<10R@9&A""-"
ML<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=8
M65IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JR
ML[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY
M^O_$`!\!``,!`0$!`0$!`0$````````!`@,$!08'"`D*"__$`+41``(!`@0$
M`P0'!00$``$"=P`!`@,1!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)R
MT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BY
MNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:``P#`0`"
M$0,1`#\`]_HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BD)P.E-
M4[E!(QF@!]%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`P\"L?PUJ@U;0+2Y)S)M,
M<O'1T)5OU4UL,.#7BO@GQ6/#?C'5=$OY`EE<7LFQFX$4NXCGT!`'TQ515T8U
M*O))7V9[92TP-FGU)L%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`G:@T57N+J*UA,L\B1H#@L[8'YT!UL6**J6NHVEX6%M<
M13;>6\MPV/RJWFD-IK<*6FY[U5@U&SNW*6US#,RC)".&(%,6Y<HIN[VI"W?M
M0`XT=JR[W7]*T]REUJ%M#(!G:\H!_*HK;Q3H=VVRWU2U=CT`E&:7,BU2FU=)
MFN>017S)XZL_L?CC686R0UP9>?\`;^;^M?3`?(R.]>$?&&P-KXPAO`"$N[93
MG/&Y3M/Z;?SK6D]3S\=!^SOV-OX;_$,@P:%K4QS]RUN7/7_88^OH:]?#9%?(
M>>_ZU[M\,?&K:W:_V3J$F=1M4^5R>9HQQD_[0XS^!JJD.J,L)B;^Y(])HIN?
M:ES6)Z0>]%4_[1LQ<BV-S")R<"/S!NSUZ5:W>U`VFMQWUI*J7>J6=@FZ[N8H
M5]9'`%9J^,?#SOL75[0M_P!=12ND4J<Y*Z3-ZEJO#<Q7,8DAD21&'#*V0:E!
MS3(::W'T4F>*:7`')%`#J*Q[GQ/HMFY2XU.UC<=5,HR/PH@\4Z'<L%BU6T=C
MT`E%+F1I[*I:]F;-%1)(L@!4@@]"#3F8*I9B`!U)-!G;4=16;_;VE=]1M!S_
M`,]E_P`:7^W=*_Z"-I_W^7_&BZ*Y)=C1HJG;:G97CLEM=0S,HR1'(&('X5/-
M/'!$TLKI'&HRS.<`?C3N*S3L2T53MM2L[MREO<PS,.2$D!(%6\TMP::W%I::
M>G/:JD&I6=S.T$-U!)(O5$D!8?A0))LNT444P"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`H[444`-KC/B<!_P`(1==_F3_T(5VE<9\3
MO^1)N_\`>3_T(5$_A9OA?XT?4\J\-ZI=>%=2L]6"_P"AW!9)`O\`&H.&_P"!
M#&:]_M;F*[MH[B!@\<BAE8'@@CBO+_#OAV/Q'\,VMP%6XCFE>!\?=?<?Y]*?
M\,O$4EO/+X<U#]W(C-Y"OU!!^9/PZC\:RIMQLF>AC8JMS2CO'?T/4I?]6P]J
M\A^$H`\0ZHP')AYX']\UZXY)4_2O)/A+_P`C#JG_`%Q'_H9K2?Q(Y*"_<U/D
M>OG`ZUY/XU\<WMUJ+:'H3.#O\IY8AEW?^XG^-=]XKU-])\,:A>QG$D<)V'_:
MZ#]:\]^$^BQSW5UJ\PW&']S$2/XCRS?7I^M*;N^4O"TXQIRK35[;>I8T7X4K
M,@N-;NY3*_S&*(]#_M,?F)_*KFI_"73I82VF7<]O,!\HD.]2?YC\#7I&.*,<
M=J?LHF3QM9RO<\5T/Q1JW@K6/[)UG?):*0'0G<8P?XT)ZK70_%K2UU;PC!JM
MOMD-FXDW@\&)^&(_\=/X5:^*6C177A\:DJ?O[-\[AU*,<,/US^%+\.ITUOP-
M+IMYB1(B]JZGNA'`_(X_"BG)PG8O&THXG#^VBK/9G@./6KFEZE<Z1J=OJ-FV
MV>W<.GH?8_49'XFK7B'1)_#FNW6F7'WHFRCXXD0_=;^GX&LFO0^)'Q[4J<O0
M^KM&U*#5])M-0MCF*XC$B\],]1^!XJQ=W"6MK+/(V%C0LQ/8"O,O@QK!N-(O
M=)D;)M9!+%SSL?J/^^@Q_P"!5N_$_5_[.\+26ZOMEO&\D8/(7JQ_[Y!KCJ>[
M<^CP?[]Q2ZG+?#ZV;Q!XUU#Q#/&"(V+H2/XFX7\E_G76>.O&8\.6Z6UKL;49
MU^3=TC7NYJ;X?:3_`&3X3MVD3;/<YGE'NW0?@H`KSFWC_P"$R^)LGV@E[9IV
M8CMY4?`'XX'_`'T:PNU%+JSU8QA5KRE)>[$N:#X'U/Q?C5M:OIDAE^9"XS(X
M]@>%7TXKJ)OA-H;6^R.:[CD'\?F[OT(Q^0KO%C5%4(`JCH`.*DQ5JFEN<U3&
MU7*\79=CPV[L?$'PWU&.6WN#)8R-A2`?+D_V67^%L>E>L>&]>MO$.CQ7]O\`
M*3Q)&3RC]Q4VMZ5!K&D75C<#='*A'/\`">Q'T/->7?"Z\GT_Q/=Z3*Q_>HV]
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MNO\`KDW\JIJR,>9SJ<S/$/`O@ZR\5&^^TSS0&WV;?)V\[MV<Y!]*[+_A3VD?
M]!&^_P#(?_Q%9WP?=8WU;<0,^5C/']^O53+&!]]?SK.$8M'H8O$5H56HLY;P
MOX$L?"][-=VUU<2O-&(V$NW&`<]E%6/'8_XHG5AU_<'M71A@RY7!'L:Y[QW_
M`,B3JW_7`U;24=#BISE.M&4M[GBNAWMYX<O;/7+:/,#2M"P'_+0#&Y3[X.17
MT!IU]!J=A#>6L@DAF0,K#N*\U\%:'#X@^'M]8R\%KIVC<#E'`4AA^-1_#O79
M]%UB;PSJ7R9E(B!/"2=U'LPY'XUE3;C9=ST<9%5^9KXH_D>LN,J?I7C'P^0?
M\+%OL`<>>>G_`$T->S%AL)]J\;^'W_)1;[_MX_\`1E7._,CFPB_=5+]CV@=*
M6D[4M:G`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`AKC/B=_R)-U_O)_Z$*[/O7&?$[_D2;K_>3_T(5$_A9T87^-'U(OA8,^#E
M_P"N\O\`Z%7/?$G0)=/OXO$FG9C<.OG,@^ZX^Z_\@:Z'X5_\B<O_`%\2_P#H
M1KKKRSAOK.:VN(P\4J%&4]P:E1O!&\JSI8J4NES&\+^((_$7A]+Q!ME4;)HS
MU1QU']?QK@?A+_R,&J#_`*8C_P!#-4M.GN?A[XTDL;AF-A<$*6)X:,GY7^H)
MP:N?"4C_`(2#4\$%3%P1_OFL^:\DGN=,J/)2J2CL[-':?$B-I/!&H;<_*JL<
M>@8$UD_"21#X=NH\@NERV<>X!%=OJEE'J6F7-E*/W<\;(?Q%>,>%=6F\#^*I
M['4P5A<^5.?[I!^63_=QG\ZN>DTS'#_O<-*DM]SW2C.!5>*YBGB$L3JR,-P8
M'@CZU*S`+DD"MCS6FG8YSQU-%!X,U1Y!E3"4`]R<?SKF/@_$ZZ7J4A'R-.J@
M^X7G^8K*^)/BA-4GCT73SYT<;@S,G.^3H$7UP?Z5W_@S0VT+PS;6D@`N&'F3
MX_OMU'X<#\*Q^*I<]*2]CA.66\F9OQ!\&)XITE9+8*-2MP6@8\;QW4_7]*^>
MKB&6VF>">)XIHV*/&XPRD=1CUKZYQ[UY]\0/`$7B.`ZCIZ"+58T],"<?W6_V
MO0_A].NG.VY\]BL-SKFCN>=_">]-IXZAAW86ZB>)ORW?S6NG\5M_PE/Q'L]&
M0[H+<A)!V_O2?^.[1^->::'>/H?B2RO)XWC>SN%,L9X88.&4_J*]6^%MA)>W
M^I:_=#,LDA12?[Q.Y_Y@5GB%>21W90^2E.H^FAZ;L$=OM4`8&!7C'PVD%GXZ
MG@F&V1XY(@#_`'@VXC\A7MN.*\0\7V-UX2\;IK-HI\F:7[3&<X!8_?0^YY/T
M/UK"HK-,]'!2YE.GU:/;LCUIU8^B:[9Z_I\=W9R95OOH?O(W<$=C6OD5JG<X
M)1<79K4:Y&P_2O%/!O\`I'Q1EEC;*>;<OD#MG_Z]=WX[\6PZ%I3V\#AM1G0K
M$@/*`\;SZ#T]36!\)]#DB2YUF96`F_=0%NK*.2P]B?Y5E+WI)+H>CATZ6'G.
M771%;XP0MY^F2#E=LB#Z_*:]#\-3I=>&M-FC(VM;1].WRC(_I67X[T%]?\-R
M10KFZA/FPCN6`Y'XC(KCOAQXPBL`-"U%A"N\_9W;@`YY0^G/K[BCX9MA;VV%
M7+O$]=JO>7`M;*:X*EA$C/@=3@9J42*W0Y^E4M:/_$EO1ZP/_(UKT//BO>29
MB^$_&,7BM;DQ6DMO]G*@^8<YW9]/I6]JG_(+NO\`KDW\C7FGP;(VZKTY:+^3
M5Z5JG_(+N?\`KDW\JE.\;G15IJG7Y8GAO@WPI)XG:\$>H/9^1M^X"=V[=UY'
MI76'X37*\GQ!/_WP?_BJA^#W#ZMGC_4]O]^O5^#44X)HZ\7BZL:KBGH9?A_2
MVT31;;3WG:=H4VF5A@M5'QV/^*(U7_K@:Z'/8_C7/>.S_P`43JH_Z8&KDO=9
MP4I-UHM[W,/X2?\`(K7!_P"GM_Y+5#XG>&G*IXAL`4GAP)]G!P.C_5?Y5?\`
MA*N?"UQU_P"/M_Y+7=2PI/"\<J*Z.,,I&00>M*,;P2.BK6=+%.7F<WX,\2)X
MET!)78"[A_=W"XQSZ_0\?K7`_#W_`)*+??\`;?\`]&&H9$N/AUXY^3)TVXZ>
MAB)_FO\`GK4OPZ8/\0[UD(96$[`^JF3(/ZBLN;WDF=BHJ%.I./PM:'M/:EI.
MU+72>*%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!112&
M@!M<WXYTJ[UKPO/9V**\[E2H9MHX8'K72XHP"*35U8JG-PDI+H<MX"TB\T3P
MTMG?QHDXF=MJMN&":ZFC''6EP*$K*P3FYR<GU..\>>%O^$ATG?;KF^MOFA[;
MO5?Q_P`*P?AKX<U;1M5O9=1M&@22%0I+`Y.[/:O3<>M&W%0Z:<N8WCBZD:+H
M]&'%<MXK\&6?B>(.2(+R,?NYU'Z-ZBNKI.U6TGHS"G4E3ES1>IX[!H?CWPH3
M'IK_`&BW!^58R'7_`+Y;I^%.N8?B/XA5K>9'M(6&&"E8E/XC+5Z_M%+MK/V7
MFSL6.>[BK]['!^$_AU;:'.M_?.MS?#E<+A(S[#UKNQQ2XHYQUJU%+1'+5JRJ
MRYI,6D(X/2G4AZ51F>0_%'P1<7-[!K.C6,L\TK;+B&$9).,A_P!,'\/Q]!\*
MZ0-$\/6=CM(D2/,F>NYN3^IK;V\]:`*'J3!<J:6S%K+UK1+/7=/>SO8]\;<@
M]T/9E/8UJ8H(HWT9<9.+NCQ^;P'XH\-WS77A^],J]@K;'*]@P/#8J1M0^)=P
M@M_LK1GH9!$BD_B37K>*-G^<5G[/LSL^NMZRBF_0\JT3X8WEY>_;O$MT9"S;
MGA5RQ<_[3'M[?K7I\,,=O"L42*D:`*JJ,``=JFP!151BD85L1.L_>88R*X/Q
M9\.;36Y)+RR=+6\<YD!7,<IQ_$/7W^O%=[S28XIM)DTJLZ3O%GC<.G?$3PZ/
M)M#+-$/N[765?P#<BII&^)6K(T#PF*-UVL"L:`@_G7KVT>@H"C'05G[+S9U?
M7GNX*_H<3\/_``G>^&K>[:^DA:2<J0L1)VX]2?K76WT;S6,\:#+,A`&>IQ5K
M%+WZU:C96.6=64Y\[W/%]*\)>.]"\W^S5@M_.QOQ)&V<9QU'H36G]E^*&/\`
MCZC_`#B_^)KU3%+@5'LUM=G0\;*6KBON.%\+P^-H]8)UZ=)+'RV``*?>R,?=
M`]ZWO%=A<:GX8U"SM4#3S0E4!;`S6UCFC%6HV5C"59N:FDD<C\/-%OM!T&:U
MU"-(YFN&D`5]W!`_P-=?2;13L4TK*R)J3=23D]V<QXS\,KXDT1X5P+N+,D#X
MZ-Z?0]/R/:N+^'GAC6=*\3?:KZR,,/D,N[>#\V17K1Y_*FA<-FI=-.5S:GBI
MPINGT9)1115G,%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
%110!_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
